NCT03962543 2025-08-07
ReNeu
SpringWorks Therapeutics, Inc.
Phase 2 Active not recruiting
Clinical Trials
4 trialsNCT05054374 2025-05-23
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02510001 2021-07-13
MErCuRIC1
University of Oxford
Phase 1 Completed
NCT02096471 2019-01-10
MEK Inhibitor
University of Alabama at Birmingham
Phase 2 Completed